Just three weeks before her 29th birthday, Dakota Middleby 's life changed in an instant. It was March 26 when she received ...

Arvinas, Inc. (NASDAQ: ARVN) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug ...

A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...

Trastuzumab deruxtecan plus pertuzumab outperformed standard-of-care therapy as first-line treatment for HER2-positive ...

New first-line therapy for HER2-positive metastatic breast cancer shows promising results in clinical trial data.